Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment

Oral Diseases (2011) 17, 433–442 Objectives:  Bone‐destructive disease treatments include bisphosphonates and antibodies against receptor activator for nuclear factor κB ligand (aRANKL). Osteonecrosis of the jaw (ONJ) is a side‐effect. Aetiopathology models failed to explain their restriction to the...

Full description

Saved in:
Bibliographic Details
Published in:Oral diseases 2011-05, Vol.17 (4), p.433-442
Main Authors: Wehrhan, F, Hyckel, P, Amann, K, Ries, J, Stockmann, P, Schlegel, KA, Neukam, FW, Nkenke, E
Format: Article
Language:English
Subjects:
Alkaline Phosphatase - analysis
aminobisphosphonate
bone
Bone Density Conservation Agents - adverse effects
Bone Morphogenetic Protein 2 - analysis
Bone Morphogenetic Protein 2 - drug effects
Bone Morphogenetic Protein 4 - analysis
Bone Morphogenetic Protein 4 - drug effects
Bone Remodeling - drug effects
Cell Count
Dentistry
Diphosphonates - adverse effects
Fibroblasts - drug effects
Fibroblasts - pathology
Humans
Imidazoles - adverse effects
Immunohistochemistry
jaw
Jaw Diseases - chemically induced
Jaw Diseases - pathology
Medical research
Msx-1
MSX1 Transcription Factor - analysis
MSX1 Transcription Factor - drug effects
ONJ
Osteoblasts - drug effects
Osteoblasts - pathology
Osteocytes - drug effects
Osteocytes - pathology
Osteonecrosis - chemically induced
Osteonecrosis - pathology
Osteopetrosis - chemically induced
RANK Ligand - analysis
RANK Ligand - drug effects
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oral Diseases (2011) 17, 433–442 Objectives:  Bone‐destructive disease treatments include bisphosphonates and antibodies against receptor activator for nuclear factor κB ligand (aRANKL). Osteonecrosis of the jaw (ONJ) is a side‐effect. Aetiopathology models failed to explain their restriction to the jaw. The osteoproliferative transcription factor Msx‐1 is expressed constitutively only in mature jaw bone. Msx‐1 expression might be impaired in bisphosphonate‐related ONJ. This study compared the expression of Msx‐1, Bone Morphogenetic Protein (BMP)‐2 and RANKL, in ONJ‐affected and healthy jaw bone. Material and methods:  An automated immunohistochemistry‐based alkaline phosphatase‐anti‐alkaline phosphatase method was used on ONJ‐affected and healthy jaw bone samples (n = 20 each): cell‐number ratio (labelling index, Bonferroni adjustment). Real‐time RT‐PCR was performed to quantitatively compare Msx‐1, BMP‐2, RANKL and GAPDH mRNA levels. Results:  Labelling indices were significantly lower for Msx‐1 (P 
ISSN:1354-523X
1601-0825
DOI:10.1111/j.1601-0825.2010.01778.x